Angion Biomedica Corp.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jay R. Venkatesan
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 51 Charles Lindbergh Boulevard Uniondale NY United States of America 11553
- IPO Date
- Feb 5, 2021
- CIK
- 0001601485
- Website
- angion.com
- Similar Companies
- Business
- Angion Biomedica Corp. Angion Biomedica Corp. (NASDAQ: ANGN), a biopharmaceutical company founded in 1998 and headquartered in Uniondale, New York, focuses on the discovery, development and commercialization of small molecule therapeutics for organ protection, regeneration and fibrotic diseases targeting acute kidney injury, chronic kidney disease, organ transplant therapy, renal fibrosis, pulmonary fibrosis, resistant hypertension, congestive heart failure, hyperaldosteronism and retinoic acid degradation; its pipeline includes lead candidate ANG-3777, a hepatocyte growth factor mimetic in Phase 2 for acute kidney injury, ANG-3070, an oral tyrosine kinase and rho kinase 2 inhibitor in Phase 1 for kidney and lung fibrotic diseases, ROCK2 inhibitors for fibrosis, CYP11B2 inhibitors for aldosterone-related conditions and CYP26 inhibitors, with preclinical assets such as anti-inflammatory compounds for COVID-19 conditions and others like ANG-4201 and ELI-008. The company primarily operates in the United States through research collaborations with academic institutions including Mount Sinai Health System, Northwestern University and NYU Langone Health, and partnerships with pharmaceutical firms for drug development and clinical trials. In June 2023, Angion Biomedica Corp. completed a reverse merger with Elicio Therapeutics, a clinical-stage biotechnology firm developing lymph node-targeted Amphiphile immunotherapies for cancer including ELI-002 for mutant KRAS-driven solid tumors in Phase 2, with the combined entity operating as Elicio Therapeutics, Inc. (NASDAQ: ELTX) headquartered in Boston, Massachusetts, following a 1-for-10 reverse stock split and name change; prior to the merger, Angion halted its Phase 2 trial of ANG-3070 in July 2022 due to safety concerns, pursued strategic alternatives and generated revenue from ANG-3777 licensing agreements and development cost recoveries in 2022 while conducting at-the-market equity offerings and public financings in 2024.
Angion (ANGN) Down on Merger Agreement With Private Biotech
New Strong Buy Stocks for November 16th
New Strong Buy Stocks for October 25th
Angion Biomedica Pulls The Plug On Another Kidney Disease Trial - Read Why
What to Know About Buying Penny Stocks on June 1st
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
Angion (ANGN) Kidney Drug Misses Third Study Goal in 2021
Angion to Present Multiple Posters at Kidney Week 2021
Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis
Angion to Participate in Upcoming September Investment Conferences
Angion Biomedica Shares Moving Higher On Encouraging Results From Early Stage Trial Of Fibrotic Disease Candidate
Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021
Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia
Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injury
Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury
Angion Biomedica: Interesting New IPO With Late Stage Asset Targeting A Novel Indication
Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated Pneumonia
Angion Announces Partial Waiver of Certain Lock-up Restrictions
ANGN Stock Price Increases Over 25% Pre-Market: Why It Happened